A post by @FirstSquawk on X.
AMGEN Q3 2026 REVENUE $10.37 BLN, ABOVE ESTIMATE OF $10.05 BLN, WITH ADJUSTED EPS $6.45, ABOVE ESTIM…
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Amgen reported third-quarter 2026 revenue of $10.37 billion, surpassing the $10.05 billion consensus estimate, alongside adjusted earnings per share of $6.45 that beat the $5.77 forecast. Adjusted operating income came in at $4.68 billion, also above the $4.33 billion estimate. The across-the-board beat on revenue, EPS and operating income signals stronger-than-expected commercial momentum and margin performance for the biopharma major. Investors will watch whether the company raises full-year guidance and how upcoming pipeline and product-level details support the outperformance.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Amgen